Last reviewed · How we verify

NCT03551951

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Recruiting now Last updated 8 October 2025
What this trial tests

trial testing Test for circulating tumor cells, DNA alterations in Non Small Cell Lung Cancer in 320 participants. Currently enrolling.

Timeline
1 July 2016
Primary endpoint
30 December 2027
30 December 2027

Quick facts

Lead sponsorUniversity of Missouri-Columbia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment320
Start date1 July 2016
Primary completion30 December 2027
Estimated completion30 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Missouri-Columbia

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
    Manjunath Y, Upparahalli SV, Avella DM, Deroche CB, et al · · 2019 · cited 67× · PMID 31212653 · DOI 10.3390/cancers11060806
  2. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives.
    Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, et al · · 2019 · cited 61× · PMID 31717773 · DOI 10.3390/cancers11111659
  3. Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease-From Early Cancer Detection to Individualized Cancer Treatment.
    David P, Mittelstädt A, Kouhestani D, Anthuber A, et al · · 2023 · cited 10× · PMID 37046585 · DOI 10.3390/cancers15071924
  4. Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules.
    Manjunath Y, Suvilesh KN, Mitchem JB, Avella Patino DM, et al · · 2022 · cited 10× · PMID 35417204 · DOI 10.1200/po.21.00378
  5. Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges.
    Dang Q, Zuo L, Hu X, Zhou Z, et al · · 2024 · cited 9× · PMID 39054866 · DOI 10.1002/cam4.70041
  6. Circulating tumor cells in pancreatic cancer: more than liquid biopsy.
    Li Z, Qin C, Zhao B, Li T, et al · · 2024 · cited 3× · PMID 39421679 · DOI 10.1177/17588359241284935

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

Other University of Missouri-Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03551951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing